Rare Merlin and King Arthur text found hidden in binding of medieval book
Variations on the classic Merlin and King Arthur legends span hundreds, if not thousands, of retellings. Many are documented within handwritten medieval manuscripts dating back over a millenia—but some editions are far rarer than others. For example, less than 40 copies are known to exist of a once-popular sequel series, the Suite Vulgate du Merlin. In 2019, researchers at the University of Cambridge discovered fragments of one more copy in their collections, tucked inside the recycled binding of a wealthy family's property record from the 16th century. But at the time of discovery, the text was impossible to read.
Now after years of painstaking collaborative work with the university's Cultural Heritage Imaging Laboratory (CHIL), archivists have finally been able to peer inside the obscured texts—without ever needing to physically handle the long-lost pages.
Experts combined multiple conservation tools and techniques to construct a 3D model of the fragments. These included multispectral imaging (MSI), which creates high-resolution images by scanning an artifact with wavelengths ranging from ultraviolet to infrared light. After borrowing X-ray and CT machines from Cambridge's zoology department, the team then examined the parchment layers to map unseen binding structures without the need to deconstruct the delicate material. CT scanning allowed researchers to examine how the pages were stitched together using thin strips of similar parchment.
Some of the Merlin texts were unreadable due to being hidden under folds or stitching, so the team also needed to amass hundreds of images from every angle using an array of magnets, prisms, mirrors, and other tools. The combined result is a high-definition, digitized 3D model of the entire relic that unfolds, allowing experts to analyze it as though reviewing the physical manuscript itself.
'If this had been done 30 years ago, the fragment might have been cut, unfolded, and flattened. But today, preserving it in situ gives us a crucial insight into 16th-century archival practices, as well as access to the medieval story itself,' Irène Fabry-Tehranchi, a French specialist in the Cambridge University Library's collections department who helped oversee the project, said in a statement.
The results revealed not just a part of Suite Vulgate du Merlin, but insights into the time period in which it existed. Experts now believe the sections originally belonged to a shortened edition of the tale. Given small typographical errors as well as the red and blue ink used in its handwritten decorated initials, historians traced its origins to sometime between 1275–1315 CE.
The original edition was written in Old French, the language used by the medieval aristocracy and courts of England after the Norman Conquest, while the 16th century binding contains two repurposed sections. Fabry-Tehranchi and colleagues at first believed it to be a 14th century story involving Sir Gawain.
'Further examination revealed it to be part of the Old French Vulgate Merlin sequel, a different and extremely significant Arthurian text,' she said.
The first portion recalls the Christians' victory against the Saxons at the Battle of Cambénic, including a fight involving Gauvain, his brothers, and his father King Loth versus the Saxon Kings Brandalus, Dodalis, Moydas, and Oriancés. The second scene is a courtly sequence that takes place during the Feast of the Assumption of the Virgin Mary, and includes Merlin appearing in Arthur's court while disguised as a harpist.
With the sections translated and digitally preserved, the team hopes the same techniques can be applied to other conservation projects, particularly those involving delicate and obscured artifacts. Recycling older parchment for new books was a common practice during the medieval era, meaning many other invaluable records are still likely hidden in existing archives.
'This project was not just about unlocking one text—it was about developing a methodology that can be used for other manuscripts,' said Fabry-Tehranchi. 'Libraries and archives around the world face similar challenges with fragile fragments embedded in bindings, and our approach provides a model for non-invasive access and study.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Singing cicadas brought back to UK from France after disappearing in 1990s
Musical insects that went extinct in the UK have been brought back to the country from France by conservationists hoping to re-establish their population. Scientists at the Species Recovery Trust this week released 11 New Forest cicadas into a specially created habitat at Paultons Park – just outside the Hampshire woods where they once sang. The New Forest cicada, Cicadetta montana, was once found across the New Forest but the last confirmed sightings were in the 1990s. Conservationists believe the insects became extinct in the UK because of changes to the way land was managed. Charlotte Carne, Species Recovery Trust project officer, said: 'This has been a really challenging project so it's amazing to see New Forest cicadas in England after all this time. 'It's like bringing them back from the dead.' The adult insects are black with distinct golden rings and transparent wings, with females growing to about 5cm while males are slightly smaller. The Trust recruited a French entomologist this week who captured the 11 female cicadas in northern France and had them shipped to the UK on Wednesday. It is understood that some of the insects are already pregnant and have been laying eggs in their specially created habitat, which is full of their favourite plants such as raspberry canes and hazel tree saplings. Because cicadas spend at least four years underground as nymphs, the trust will not know until 2029 at the earliest whether this phase of the project has been successful. If they survive, the conservationists can release the adults at secret locations in the New Forest. In the meantime, the team said it hopes to import more cicadas from France to continue the breeding programme at Paultons Park. They are also studying populations of the same species in Slovenia to learn more about their behaviour. Dominic Price, Species Recovery Trust director, said: 'We believe the New Forest cicada probably went extinct because of changes to the way land was managed, but we have worked with Forestry England to put the right kind of management in place. 'What's more, we think that our warming climate could also favour their survival, so we are very hopeful that one day soon, cicadas will sing in the New Forest again.' The first-of-its-kind project has been funded by Natural England, the Swire Charitable Trust and the Valentine Charitable Trust. Graham Horton, acting deputy director for the Thames Solent Area Team at Natural England, said: 'This project represents a remarkable achievement, showcasing the dedication, innovation and teamwork that made it possible. 'After years of absence, we finally have New Forest cicada on English shores again and we look forward to the next phase of the project to explore re-establishing this species in the New Forest.'


CBS News
12 hours ago
- CBS News
Underwater military drone accidentally stumbles upon deepest shipwreck ever found off France: "As if time froze"
What technology could change the way we learn about shipwrecks What technology could change the way we learn about shipwrecks What technology could change the way we learn about shipwrecks Archaeologists have discovered by chance what they say are the remains of a 16th-century merchant ship more than 1.5 miles underwater off southern France, the deepest such find in its section of the Mediterranean or any other French waters. Archaeologists believe the ship was sailing from northern Italy loaded with ceramics and metal bars before it sunk. Despite a little modern waste dotting its sunken cargo at 8,422 feet below sea level, researchers were excited about the potential of an archaeological site largely preserved intact. "It's the deepest shipwreck ever found in French territorial waters," Arnaud Schaumasse, the head of the culture ministry's underwater archaeology department, said late Wednesday. France's Department of Underwater and Submarine Archaeological Research released images of the shipwreck on social media, saying the vessel was discovered "during a military operation to explore the seabed." Archaeologists say they discovered by chance what they say are the remains of a 16th-century merchant ship more than 1.5 miles underwater off southern France. National Navy via France's Department of Underwater and Submarine Archaeological Research An underwater drone stumbled upon the sunken ship by chance in early March in waters near Saint-Tropez in southeastern France, deputy maritime prefect Thierry de la Burgade said. "The sonar detected something quite big, so we went back with the device's camera, then against with an underwater robot to snap high-quality images," he said. The drone was patrolling the seabed as part of a government project to explore and monitor France's deep-sea resources, from minerals to deep-sea internet cables. Archaeologist Marine Sadania said experts discovered 200 jugs with pinched spouts among the wreckage at the site they have dubbed "Camarat 4." Some of these jugs were marked with the monogram "HIS," the first three letters of the Greek name of Jesus, or covered with plant-inspired or geometric patterns. Those details seemed to indicate the jugs hailed from the Liguria region in what is now northern Italy, she said. "Camarat 4 is a remarkable discovery for its depth, unprecedented character and the opportunity it offers to study an almost intact 16th-century wreck," France's Department of Underwater and Submarine Archaeological Research said. "As if time froze" Experts also identified piles of around 100 yellow plates, two cauldrons, an anchor and six cannons. Modern waste, such as a soda can or an empty yogurt container, were spotted too. One image released by officials appeared to show an aluminum can next to an anchor. Archaeologists say they discovered by chance what they say are the remains of a 16th-century merchant ship more than 1.5 miles underwater off southern France. National Navy via France's Department of Underwater and Submarine Archaeological Research But despite this, "the site -- thanks to its depth which prevented any recovery or looting -- has remained intact, as if time froze, which is exceptional," Sadania said. Over the coming two years, she and colleagues plan to draw up a 3D digital version of the ship, as well as extract samples from the site to better study them before returning them to the public domain. According to the defense ministry in charge of exploring France's deep seas, researchers can remove an item from a shipwreck by guiding a submarine robot with pincers or arms, via a long cable linking the device to a boat on the surface. Officials said further analysis will be carried out by ceramic experts, archaeologists and specialists in naval architecture. The deepest French authorities had found a sunken vessel until now was 2.3 kilometers under sea level off the southern city of Toulon in 2019. The wreckage belonged to La Minerve, a French submarine that plunged to its demise in 1968 with 52 navy crew on board, only four minutes after the start of a routine assignment.
Yahoo
15 hours ago
- Yahoo
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
Agreement to consider opening the French Early Access Program expeditiously after approval of a dose-ranging study Design for dose-ranging study submitted, with clinical trial application targeted for Q3 2025 Opening of AAC targeted for Q4 2025 at the latest Multiple near-term value catalysts expected over next 12 months PARIS, June 12, 2025--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ® upon approval of a dose-ranging clinical study. Clear Path Forward for LUMEVOQ® AAC Program in France Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize the protocol of a dose-ranging study in Q3 2025. In parallel, the Company will work with the agency to find a solution for patients who may not be included in the study but who may benefit from the AAC program. The AAC program is targeted to open in Q4 2025 at the latest. "In the interest of clearing the way for patients to be treated with LUMEVOQ, we are pleased to have achieved this important agreement with ANSM on a clear path forward for opening patient access to LUMEVOQ in France" said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "We are thankful for the ANSM's ongoing engagement and openness to discussion, as we work towards the shared goal of providing access to LHON patients who urgently need a safe and effective treatment." Financing Strategy to Support Regulatory Milestones GenSight is implementing a financing strategy to bridge operations through the opening of the AAC program and prepare for the new global Phase III clinical trial. The Company is actively pursuing various funding initiatives to support these critical regulatory milestones. "We are working on our financing strategy to manage the bridge between now and the opening of the AAC program and the initiation of the Phase III study," commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "Our focus remains on securing the resources needed to execute our regulatory strategy while exploring additional funding opportunities. " Advancing Core Marketing Authorization Strategy In parallel with the French AAC program developments, GenSight will continue to advance its global marketing authorization strategy: Preparation for regulatory consultations in the US and EU Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements Completing the transition to a new manufacturing partner to secure reliable clinical and commercial supply Advancing preparations for MHRA submission in the United Kingdom During this period, the Company will actively pursue additional non-dilutive funding opportunities, including licensing arrangements outside North America and Europe and potential M&A activities. Multiple Value Catalysts GenSight anticipates a number of significant value-creating events in 2025-2026: Q3 2025: Clinical trial application for focused dose-ranging study Q4 2025: Completion of manufacturing tech transfer Q4 2025: Opening of the AAC program Q2 2026: Completion of Phase III trial preparations Early H2 2026: Initiation of global Phase III clinical trial Early H2 2026: pre-submission meeting with MHRA Financial Position The Company received €0.7 million of its Research Tax Credit (CIR) end of May, with the remaining €0.4 million to be paid in July 2025. Based on current operations and projections, GenSight's cash will support operations until mid-July 2025. The Company acknowledges that current funds are insufficient to cover operational requirements for the next 12 months. The planned financing initiatives are designed to extend the cash runway and enable the initiation of the Phase III clinical trial and UK MHRA marketing application for LUMEVOQ®. As of June 12, 2025, the number of outstanding GenSight Biologics shares was 131,466,495 ordinary shares. Risk factors Detailed information regarding the Company, including its business, financial information, results, perspectives and related risk factors are contained (i) in the Company's 2024 Universal Registration Document filed with the AMF on April 8, 2025 under number D.25-0234. This document, as well as other regulated information and all of the Company's press releases, can be accessed on the Company's website ( and/or AMF ( The reader's attention is drawn to the risk factors related to the Company and its activities presented in chapter 3 of its 2024 URD in particular the liquidity risk presented in the chapter 3.1.1. About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. While the Company is actively pursuing financing solutions, regulatory requirements necessitate disclosure that material uncertainty exists regarding the Company's ability to continue as a going concern if sufficient funding cannot be secured. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics' regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release. View source version on Contacts GenSight Biologics Chief Financial Officer Jan Eryk Umiastowski jeumiastowski@